Medgenics: ASGCT 2015 (Medgenics) - Jun 17, 2015 - “TARGT procedures are well tolerated and good safety has been observed thus far with TARGTEPO”; “Average duration of eEPO secretion at the low dose cohort is current at 4.75 months (patients are still in an ongoing follow-up with functioning TARGTs hence duration of effect continue to increase) from a single implantation with 3 out of 6 patient at or above 5 months”
P1/2 data • Biosimilar
|